Tianjin Chase Sun Pharmaceutical Co., Ltd (China)

Tianjin Chase Sun Pharmaceutical Co., Ltd is a company based in Tianjin, China. It is a diversified enterprise group that operates in various fields including modern traditional Chinese medicine, chemical synthesis drugs, biotechnology drugs, and medical devices. The company is involved in research and development, production, marketing, and capital operations. It has been recognized for its outstanding performance and has consistently ranked on the Forbes China Potential Enterprises List since its listing. The company's research and development areas cover a wide range of diseases, including sepsis, cancer, immune regulation, blood disorders, neurological disorders, anesthesia, respiratory diseases, and vascular diseases. It has developed a new Chinese medicine drug called Xue Bi Jing Injection, which is approved by the National Medical Products Administration for the treatment of systemic inflammatory response syndrome (SIRS), sepsis, and multiple organ dysfunction syndrome (MODS). The company has also established a technology transfer center in Tianjin, which serves as a high-tech conversion base for innovative projects and industrialization channels. The center integrates multiple pilot production lines for traditional Chinese medicine, biotechnology, small molecule compound synthesis, peptide synthesis, polysaccharide synthesis, formulation, and quality analysis.